A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2017; you can also visit the original URL.
The file type is
her second cycle. The median progression-free interval was 1.7 months (range 0.9-5.8) and overall survival was 6.9 months (1.6-23.7). Conclusions: Docetaxel has limited activity in patients with recurrent cancer of the cervix at the dose and schedule tested. Abstract Background/Aims: A phase II study was conducted to assess the activity and toxicity of weekly docetaxel in patients with advanced or recurrent cancer of the cervix. Methods: Eligible patients were required to have measurabledoi:10.1159/000106489 pmid:17664880 fatcat:punhgkrufrat3fzl3a4q32sjiq